Europe Lymphedema Treatment Market - Industry Trends and Forecast to 2029
- Published Date: 2022-11-21
- Report ID: 144451
- Pages: 200
-
Format:
Short Description:
Europe Lymphedema Treatment Market, By Treatment Type (Compression Therapy, Surgery, Drug Therapy, Laser Therapy and Others), Treatment (Primary Lymphedema and Secondary Lymphedema), Affected Area (Genital, Lower Extremity, Upper Extremity and Others), Age Group (Adult and Geriatric), Route of Administration (Oral, Injectable and Others), End User (Hospitals, Ambulatory Surgical Centres, Speciality Clinics and Others), Distribution Channel (Direct Tender, Pharmacy Stores, and Others), Country (Germany, France, U.K., Hungary, Lithuania, Austria, Ireland, Norway, Poland, Italy, Spain, Switzerland, Netherlands, Belgium, Russia, Turkey, and Rest of Europe) Industry Trends and Forecast to 2029
Market Definition:
Lymphedema refers to swelling that generally occurs in upper and lower extremities. Sometimes both arms and both legs swell. Lymphedema is most commonly caused by the removal of or damage to lymph nodes as a part of cancer treatment. It results from a blockage in lymphatic system, which is part of immune system. Stems from a damaged lymphatic system, can lead to infections, disfigurement, debilitating pain and disability. There is no cure for lymphedema.
Lymphedema treatment involves multiple therapies instead of standard treatment, since the patients are dissatisfied or dont get cured with the conventional treatment of lymphedema. They approach the alternative treatment which offers more control over health care decisions, and the alternatives are found to be more compatible with the patients health system.
Lymphedema can occur after any cancer or its treatment that affects lymph node drainage. It has been reported to occur within days and up to 30 years after treatment for breast cancer. The initial stage lymphedema treatments are therapies, surgeries and lymphovenous transplant among others. But there is no permanent cure for lymphedema.
Market Segmentation:
Europe lymphedema treatment market is categorized into seven notable segments which are by treatment type, type, affected area, age group, route of administration, end user, and distribution channel.
On the basis of treatment type, Europe lymphedema treatment market is segmented in compression therapy, surgery, drug therapy, laser therapy and others
On the basis of type, Europe lymphedema treatment market is segmented in primary lymphedema and secondary lymphedema
On the basis of affected area, Europe lymphedema treatment market is segmented genital, lower extremity and upper extremity
On the basis of age group, the Europe lymphedema treatment market is segmented into adult and geriatric
On the basis of route of administration, Europe lymphedema treatment market is segmented in oral, injectable and others
On the basis of end user, Europe lymphedema treatment market is segmented in hospitals, ambulatory surgical centres, speciality clinics and others
On the basis of distribution channel, Europe lymphedema treatment market is segmented in direct tender, pharmacy stores and others
Market Players:
The key market players for the Europe lymphedema treatment market are listed below:
Cardinal Health
Smith+Nephew
SIGVARIS GROUP
medi GmbH & Co. KG
PAUL HARTMANN AG
Convatec Inc.
3M
Juzo
Huntleigh Healthcare Limited
HERANTIS PHARMA Plc
Lohmann & Rauscher GmbH & Co. KG
Sanyleg Srl a socio unico
Essity (BSN medical GmbH)
TABLE OF CONTENTS
1 INTRODUCTION 43
1.1 OBJECTIVES OF THE STUDY 43
1.2 MARKET DEFINITION 43
1.3 OVERVIEW OF EUROPE LYMPHEDEMA TREATMENT MARKET 43
1.4 LIMITATIONS 45
1.5 MARKETS COVERED 45
2 MARKET SEGMENTATION 48
2.1 MARKETS COVERED 48
2.2 GEOGRAPHICAL SCOPE 49
2.3 YEARS CONSIDERED FOR THE STUDY 50
2.4 CURRENCY AND PRICING 50
2.5 DBMR TRIPOD DATA VALIDATION MODEL 51
2.6 MULTIVARIATE MODELLING 54
2.7 PRODUCT TYPE LIFELINE CURVE 55
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 55
2.9 DBMR MARKET POSITION GRID 57
2.10 MARKET APPLICATION COVERAGE GRID 58
2.11 VENDOR SHARE ANALYSIS 59
2.12 SECONDARY SOURCES 60
2.13 ASSUMPTIONS 60
3 EXECUTIVE SUMMARY 61
4 PREMIUM INSIGHTS 65
4.1 PESTEL'S ANALYSIS 67
4.2 PORTER'S MODEL 68
5 PIPELINE ANALYSIS FOR EUROPE LYMPHEDEMA TREATMENT MARKET 69
6 EPIDEMIOLOGY 70
7 REGULATORY GUIDELINES FOR EUROPE LYMPHEDEMA TREATMENT MARKET 71
7.1 U.S. 71
7.2 EUROPE 72
7.3 INDIA 72
7.4 MEXICO 73
7.5 CANADA 73
8 MARKET OVERVIEW 75
8.1 DRIVERS 77
8.1.1 RISE IN THE NUMBER OF LYMPHEDEMA CASES EUROPELY 77
8.1.2 INCREASE IN THE PREVALENCE OF CANCERS 77
8.1.3 INCREASING NUMBER OF HEALTHCARE FACILITIES 78
8.1.4 MULTIPLE THERAPIES 78
8.2 RESTRAINTS 79
8.2.1 HIGH COST OF TREATMENT 79
8.2.2 LACK OF AWARENESS ABOUT THE DISEASE 80
8.3 OPPORTUNITIES 80
8.3.1 DRUG APPROVALS 80
8.3.2 PARTNERSHIP AND AGREEMENT BY MAJOR PLAYERS 81
8.4 CHALLENGES 81
8.4.1 NO PERMANENT CURE FOR LYMPHEDEMA 81
8.4.2 DIFFICULT REIMBURSEMENT 82
9 IMPACT OF COVID-19 ON THE EUROPE LYMPHEDEMA TREATMENT MARKET 83
9.1 IMPACT ON PRICE 83
9.2 IMPACT ON DEMAND 83
9.3 IMPACT ON SUPPLY CHAIN 84
9.4 STRATEGIC DECISIONS OF GOVERNMENT AND MANUFACTURERS 84
9.5 CONCLUSION 84
10 EUROPE LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE 86
10.1 OVERVIEW 87
10.2 COMPRESSION THERAPY 90
10.2.1 BY PRODUCT 90
10.2.1.1 COMPRESSION PUMPS 90
10.2.1.2 COMPRESSION GARMENTS 90
10.2.1.2.1 COMPRESSION STOCKINGS 91
10.2.1.2.2 COMPRESSION SLEEVES 91
10.2.1.2.3 OTHERS 91
10.2.1.3 COMPRESSION BANDAGES & WRAPS 91
10.2.1.4 OTHERS 91
10.2.2 BY TECHNIQUE 92
10.2.2.1 STATIC COMPRESSION THERAPY 92
10.2.2.2 DYNAMIC COMPRESSION THERAPY 92
10.3 SURGERY 92
10.3.1 LYMPHOVENOUS TRANSPLANT 93
10.3.2 LYMPHATICOVENOUS ANASTOMOSIS 93
10.3.3 LIPOSUCTION 93
10.3.4 OTHERS 93
10.4 DRUG THERAPY 93
10.4.1 NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) 94
10.4.2 RETINOIDS 94
10.4.3 ANTIBIOTICS 94
10.4.4 OTHERS 94
10.5 LASER THERAPY 95
10.6 OTHERS 96
11 EUROPE LYMPHEDEMA TREATMENT MARKET, BY TYPE 97
11.1 OVERVIEW 98
11.2 SECONDARY LYMPHEDEMA 101
11.3 PRIMARY LYMPHEDEMA 101
11.3.1 LYMPHEDEMA PRAECOX (MEIGE DISEASE) 102
11.3.2 CONGENITAL LYMPHEDEMA 102
11.3.3 LYMPHEDEMA TARDA 102
12 EUROPE LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA 103
12.1 OVERVIEW 104
12.2 LOWER EXTREMITY 107
12.3 UPPER EXTREMITY 107
12.4 GENITALIA 108
13 EUROPE LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP 109
13.1 OVERVIEW 110
13.2 ADULT 113
13.3 GERIATRIC 113
13.4 PEDIATRIC 114
14 EUROPE LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 115
14.1 OVERVIEW 116
14.2 ORAL 119
14.3 INJECTABLE 119
14.4 TOPICAL 120
15 EUROPE LYMPHEDEMA TREATMENT MARKET, BY END USER 121
15.1 OVERVIEW 122
15.2 HOSPITAL 125
15.3 SPECIALTY CLINICS 125
15.4 AMBULATORY SURGICAL CENTERS 126
15.5 OTHERS 126
16 EUROPE LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL 127
16.1 OVERVIEW 128
16.2 PHARMACY STORES 131
16.3 DIRECT TENDER 131
16.4 OTHERS 132
17 EUROPE LYMPHEDEMA TREATMENT MARKET, BY REGION 133
17.1 EUROPE 134
17.1.1 GERMANY 142
17.1.2 FRANCE 146
17.1.3 UNITED KINGDOM 150
17.1.4 ITALY 154
17.1.5 RUSSIA 158
17.1.6 SPAIN 162
17.1.7 TURKEY 166
17.1.8 NETHERLANDS 170
17.1.9 SWITZERLAND 174
17.1.10 BELGIUM 178
17.1.11 POLAND 182
17.1.12 AUSTRIA 186
17.1.13 HUNGARY 190
17.1.14 NORWAY 194
17.1.15 IRELAND 198
17.1.16 LITHUANIA 202
17.1.17 REST OF EUROPE 206
18 EUROPE LYMPHEDEMA TREATMENT MARKET: COMPANY LANDSCAPE 207
18.1 COMPANY SHARE ANALYSIS: EUROPE 207
19 SWOT ANALYIS 208
20 COMPANY PROFILE 209
20.1 TACTILE MEDICAL 209
20.1.1 COMPANY SNAPSHOT 209
20.1.2 REVENUE ANALYSIS 209
20.1.3 COMPANY SHARE ANALYSIS 210
20.1.4 PRODUCT PORTFOLIO 210
20.1.5 RECENT DEVELOPMENT 210
20.1.6 CLINICAL TRIAL: 210
20.2 ESSITY (BSN MEDICAL GMBH) 211
20.2.1 COMPANY SNAPSHOT 211
20.2.2 COMPANY SHARE ANALYSIS 211
20.2.3 PRODUCT PORTFOLIO 211
20.2.4 RECENT DEVELOPMENT 212
20.3 3M 213
20.3.1 COMPANY SNAPSHOT 213
20.3.2 REVENUE ANALYSIS 213
20.3.3 COMPANY SHARE ANALYSIS 214
20.3.4 PRODUCT PORTFOLIO 214
20.3.5 RECENT DEVELOPMENTS 214
20.3.6 NEW BUSINESS SEGMENT 214
20.3.7 ACQUISITION 215
20.4 CARDINAL HEALTH 216
20.4.1 COMPANY SNAPSHOT 216
20.4.2 REVENUE ANALYSIS 216
20.4.3 COMPANY SHARE ANALYSIS 217
20.4.4 PRODUCT PORTFOLIO 217
20.4.5 RECENT DEVELOPMENT 217
20.5 LOHMANN & RAUSCHER GMBH & CO. KG 218
20.5.1 COMPANY SNAPSHOT 218
20.5.2 COMPANY SHARE ANALYSIS 218
20.5.3 PRODUCT PORTFOLIO 219
20.5.4 RECENT DEVELOPMENT 219
20.6 AIROS MEDICAL, INC. 220
20.6.1 COMPANY SNAPSHOT 220
20.6.2 PRODUCT PORTFOLIO 220
20.6.3 RECENT DEVELOPMENT 220
20.6.4 PRODUCT LAUNCH: 220
20.7 AVET PHARMACEUTICALS INC. 221
20.7.1 COMPANY SNAPSHOT 221
20.7.2 PRODUCT PORTFOLIO 221
20.7.3 RECENT DEVELOPMENT 221
20.8 BIOCOMPRESSION SYSTEMS 222
20.8.1 COMPANY SNAPSHOT 222
20.8.2 PRODUCT PORTFOLIO 222
20.8.3 RECENT DEVELOPMENT 223
20.8.4 AGREEMENT 223
20.9 CONVATEC INC. 224
20.9.1 COMPANY SNAPSHOT 224
20.9.2 PRODUCT PORTFOLIO 224
20.9.3 RECENT DEVELOPMENT 224
20.10 HERANTIS PHARMA PLC 225
20.10.1 COMPANY SNAPSHOT 225
20.10.2 RECENT DEVELOPMENT 225
20.11 HUNTLEIGH HEALTHCARE LIMITED 226
20.11.1 COMPANY SNAPSHOT 226
20.11.2 PRODUCT PORTFOLIO 226
20.11.3 RECENT DEVELOPMENT 226
20.12 JUZO 227
20.12.1 COMPANY SNAPSHOT 227
20.12.2 PRODUCT PORTFOLIO 227
20.12.3 RECENT DEVELOPMENT 227
20.13 KOYA MEDICAL 228
20.13.1 COMPANY SNAPSHOT 228
20.13.2 PRODUCT PORTFOLIO 228
20.13.3 RECENT DEVELOPMENT 228
20.13.4 APPROVAL 228
20.14 MEDI GMBH & CO. KG 229
20.14.1 COMPANY SNAPSHOT 229
20.14.2 PRODUCT PORTFOLIO 229
20.14.3 RECENT DEVELOPMENT 229
20.15 MEGO AFEK LTD 230
20.15.1 COMPANY SNAPSHOT 230
20.15.2 PRODUCT PORTFOLIO 230
20.15.3 RECENT DEVELOPMENT 231
20.15.4 APPLICATION LAUNCH: 231
20.16 PAUL HARTMANN AG 232
20.16.1 COMPANY SNAPSHOT 232
20.16.2 REVENUE ANALYSIS 232
20.16.3 PRODUCT PORTFOLIO 233
20.16.4 RECENT DEVELOPMENTS 233
20.17 SANYLEG SRL A SOCIO UNICO 234
20.17.1 COMPANY SNAPSHOT 234
20.17.2 PRODUCT PORTFOLIO 234
20.17.3 RECENT DEVELOPMENT 234
20.18 SIGVARIS GROUP 235
20.18.1 COMPANY SNAPSHOT 235
20.18.2 PRODUCT PORTFOLIO 235
20.18.3 RECENT DEVELOPMENTS 236
20.18.4 PRODUCT LAUNCHES: 236
20.19 SMITH +NEPHEW 237
20.19.1 COMPANY SNAPSHOT 237
20.19.2 REVENUE ANALYSIS 237
20.19.3 PRODUCT PORTFOLIO 238
20.19.4 RECENT DEVELOPMENT 238
20.20 THERMOTEK 239
20.20.1 COMPANY SNAPSHOT 239
20.20.2 PRODUCT PORTFOLIO 239
20.20.3 RECENT DEVELOPMENT 239
21 QUESTIONNAIRE 240
22 RELATED REPORTS 244
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
